Psoriasis is an immune-related, chronic, and recurrent skin disease that affects approximately 2% of the population. 

Recently, our company's research and development team identified a new target, SKP2, that can be used to treat this disease. Through rigorous compound screening and optimization, our team has developed an extended-release tablet of an SKP2 inhibitor for the treatment of psoriasis. 

This medication targets the SKP2 protein, helping to regulate the cell cycle and reduce the hyperproliferation of keratinocytes, thereby treating psoriasis.